您的位置: 首页 > 农业专利 > 详情页

transdermal administration of (2s) - (4e) -n-methyl-5- (3- (5-isopropoxypyridin) yl-4-penten-2-amine
专利权人:
Astrazeneca AB;Targacept. Inc.
发明人:
Johannes Antonius Maria Neelissen,John W. James,Merouane Bencherif,P.H.D., Michael G. Williams
申请号:
BRPI0815070
公开号:
BRPI0815070A2
申请日:
2008.07.30
申请国别(地区):
BR
年份:
2018
代理人:
摘要:
The present invention generally relates to the transdermal administration of (2S)-(4E)-N-methyl-5-(3-(5-isopropoxypyridin)yl)-4-penten-2-amine, or pharmaceutically acceptable salts thereof. The transdermal administration can be effected using transdermal drug delivery devices, semi-solid dosage forms, or iontophoresis. The drug delivery devices and/or semi-solid dosage forms can provide instantaneous release, sustained release, or combinations thereof, and can include permeation enhancers and other components to assist in drug transport across the dermis, especially the epidermis. The compositions can be used to treat and/or prevent any indication which the active ingredients are capable of treating and preventing, but deliver (2S)-(4E)-N-methyl-5-(3-(5-isopropoxypyridin)yl)-4-penten-2-amine, or pharmaceutically acceptable salts thereof, in an efficacious manner. Disorders that can be treated and/or prevented include central nervous system disorders, addictions, pain, and inflammation.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/
相关发明人
相关专利

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充